New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology

Alba A. Brandes, Marco Bartolotti, Gianluca Marucci, Claudio Ghimenton, Raffaele Agati, Antonio Fioravanti, Maurizio Mascarin, Lorenzo Volpin, Franco Ammannati, Barbara Masotto, Marina Paola Gardiman, Dario De Biase, Giovanni Tallini, Girolamo Crisi, Stefania Bartolini, Enrico Franceschi

Research output: Contribution to journalArticlepeer-review


Medulloblastoma is the most common central nervous system tumor in children, while it is extremely rare in adults. Multimodal treatment involving surgery, radiotherapy and chemotherapy can improve the prognosis of this disease, and recent advances in molecular biology have allowed the identification of molecular subgroups (WNT, SHH, Groups 3 and 4), each of which have different cytogenetic, mutational and gene expression signatures, demographics, histology and prognosis.The present review focuses on the state of the art for adult medulloblastoma treatment and on novel molecular advances and their future implications in the treatment of this disease.

Original languageEnglish
Pages (from-to)348-359
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Issue number3
Publication statusPublished - Jun 1 2015


  • Adults
  • Medulloblastoma
  • SHH
  • Treatment
  • WNT

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)


Dive into the research topics of 'New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology'. Together they form a unique fingerprint.

Cite this